Placebo News and Research

RSS

Evaluating the trustworthiness and characteristics of COVID-19-related trial preprints

Researchers investigated the impact and trustworthiness of trial preprints on COVID-19-related decision-making.

7 Apr 2022

Study shows circular RNA vaccine provides robust protection against SARS-CoV-2 in mice and rhesus macaques

Researchers investigated the effectiveness of a circRNA vaccine against SARS-CoV-2 and its Delta and Omicron variants, which elicited significant antibody and T-cell responses in mice and rhesus macaques.

6 Apr 2022

Sodium thiosulfate shows no benefits for reducing heart damage following a heart attack

Sodium thiosulfate showed no benefits for reducing injury to damaged areas of heart muscle following a heart attack, in a study presented at the American College of Cardiology's 71st Annual Scientific Session.

5 Apr 2022

Low-fat vegan diet improves joint pain in patients with rheumatoid arthritis

A low-fat vegan diet, without calorie restrictions, improves joint pain in patients with rheumatoid arthritis, according to a new study conducted by researchers at the Physicians Committee for Responsible Medicine and published in the American Journal of Lifestyle Medicine. Study participants also experienced weight loss and improved cholesterol levels.

4 Apr 2022

Experimental heart failure drug has little impact on exercise tolerance

Heart failure patients taking the investigational drug omecamtiv mecarbil, which has been previously shown to improve long-term outcomes, see little impact on their ability to exercise compared to a placebo, according to a study supported by the Duke Clinical Research Institute.

4 Apr 2022

COVID-19 study proves ivermectin ineffective

A recent study published in the New England Journal of Medicine investigated the impact of ivermectin, an antiparasitic drug, as an early treatment option among coronavirus disease 2019 (COVID-19) patients.

4 Apr 2022

Addition of alirocumab to high-intensity statin treatment reduces key measures of plaque vulnerability

Compared with a placebo, the addition of the injectable cholesterol-lowering drug alirocumab to high-intensity statin treatment in patients who have had a heart attack resulted in twofold greater reductions in three key measures of plaque vulnerability that signal risk for future cardiac events, according to research presented at the American College of Cardiology's 71st Annual Scientific Session.

3 Apr 2022

Experimental siRNA therapeutic shows promise to reduce an important driver of heart disease risk

While there are effective therapies to reduce the risk of heart disease by lowering low-density lipoprotein (LDL), or "bad" cholesterol, and other lipids, to date there are no approved treatments to lower lipoprotein(a), a lesser-known driver of heart disease risk.

3 Apr 2022

Experimental heart failure drug does not improve exercise capacity in HFrEF patients

Patients with heart failure with reduced ejection fraction (HFrEF) did not experience any improvement in their ability to exercise vigorously after taking the experimental heart failure drug omecamtiv mecarbil, in a study presented at the American College of Cardiology's 71st Annual Scientific Session.

3 Apr 2022

Patiromer lowers hyperkalemia risk in heart failure patients taking RAASi therapy

Patients taking renin-angiotensin-aldosterone system inhibitor (RAASi) medications for heart failure had significantly lower blood potassium levels when taking patiromer—a drug that helps to prevent the body from absorbing too much potassium—compared with a placebo, in a study presented at the American College of Cardiology's 71st Annual Scientific Session.

3 Apr 2022

Extension study shows mavacamten’s efficacy and safety in treating hypertrophic cardiomyopathy

Use of mavacamten, a novel cardiac myosin inhibitor, to treat people with symptomatic obstructive hypertrophic cardiomyopathy (HCM), a condition that results in excess thickening of the heart muscle, resulted in continued benefits in patient quality of life and outcomes over an extended period of time, according to interim data from the EXPLORER-HCM extension study presented at the American College of Cardiology's 71st Annual Scientific Session.

3 Apr 2022

Global study demonstrates some benefits of flu vaccine in people with heart failure

People with heart failure who received an annual flu shot had lower rates of pneumonia and hospitalization on a year-round basis and a reduction in major cardiovascular events during peak flu season, in a study presented at the American College of Cardiology's 71st Annual Scientific Session.

3 Apr 2022

Investigational drug vupanorsen reduces non-HDL cholesterol by up to 28%

The investigational drug vupanorsen reduced total levels of non-high-density lipoprotein (non-HDL) cholesterol by up to 28% in patients with high cholesterol who were already taking a cholesterol-lowering statin medication, in a study presented at the American College of Cardiology's 71st Annual Scientific Session.

3 Apr 2022

Multi-mineral supplement could help reduce downstream consequences of fatty liver disease

Results from a preclinical study add new evidence that a multi-mineral dietary supplement known as Aquamin could be a simple and effective way to reduce the long-term health consequences of non-alcoholic fatty liver disease.

3 Apr 2022

Experimental siRNA therapy reduces a key driver of heart disease risk by up to 98%

Findings from a new Cleveland Clinic-led phase 1 trial show that an experimental "gene silencing" therapy reduced blood levels of lipoprotein(a), a key driver of heart disease risk, by up to 98%.

3 Apr 2022

Experimental drug for hypertrophic cardiomyopathy reduces the need for invasive procedures, trial shows

Findings from a Cleveland Clinic-led clinical trial showed that the use of an experimental drug in severely symptomatic, hypertrophic cardiomyopathy patients significantly reduced the need for invasive procedures.

2 Apr 2022

Convalescent plasma treatment for newly diagnosed COVID-19 patients may reduce hospitalization risk

Early treatment of newly diagnosed COVID-19 patients with plasma extracted from individuals who have recovered from the disease reduces the need for hospitalization by more than 50%, according to a new nationwide clinical trial.

31 Mar 2022

Results of Phase 3 Nanocovax SARS-CoV-2 vaccine trial suggest robust effectiveness

A new study presented the findings of the Phase 3 trial of the Nanocovax coronavirus disease 2019 (COVID-19) vaccine.

29 Mar 2022

Novel drug combination can boost chemoimmunotherapy response in bladder cancer patients

Adding an anti-inflammatory medication to immunotherapy and standard chemotherapy drugs may provide long-term suppression of aggressive bladder tumor growth, according to a proof-of-concept study led by Cedars-Sinai Cancer investigators.

28 Mar 2022

Depression occurs independently of inflammation for many older people, study suggests

Multiple prior studies have found higher levels of inflammation in older individuals with depression. Now, a new Penn Medicine study has found that clinically depressed older individuals, on average, don't have elevated levels of inflammation if they don't already have other inflammatory conditions such as arthritis.

28 Mar 2022

Placebo News and Research

Evaluating the trustworthiness and characteristics of COVID-19-related trial preprints

Study shows circular RNA vaccine provides robust protection against SARS-CoV-2 in mice and rhesus macaques

Sodium thiosulfate shows no benefits for reducing heart damage following a heart attack

Low-fat vegan diet improves joint pain in patients with rheumatoid arthritis

Experimental heart failure drug has little impact on exercise tolerance

COVID-19 study proves ivermectin ineffective

Addition of alirocumab to high-intensity statin treatment reduces key measures of plaque vulnerability

Experimental siRNA therapeutic shows promise to reduce an important driver of heart disease risk

Experimental heart failure drug does not improve exercise capacity in HFrEF patients

Patiromer lowers hyperkalemia risk in heart failure patients taking RAASi therapy

Extension study shows mavacamten’s efficacy and safety in treating hypertrophic cardiomyopathy

Global study demonstrates some benefits of flu vaccine in people with heart failure

Investigational drug vupanorsen reduces non-HDL cholesterol by up to 28%

Multi-mineral supplement could help reduce downstream consequences of fatty liver disease

Experimental siRNA therapy reduces a key driver of heart disease risk by up to 98%

Experimental drug for hypertrophic cardiomyopathy reduces the need for invasive procedures, trial shows

Convalescent plasma treatment for newly diagnosed COVID-19 patients may reduce hospitalization risk

Results of Phase 3 Nanocovax SARS-CoV-2 vaccine trial suggest robust effectiveness

Novel drug combination can boost chemoimmunotherapy response in bladder cancer patients

Depression occurs independently of inflammation for many older people, study suggests

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News